Navigation Links
Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
Date:2/6/2008

BERKELEY, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced that the first heart failure patient has been dosed in its Phase Ib, multi-center, open-label, ascending dose clinical study of the company's lead product candidate, CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

"We are very excited that dosing has begun in this important dose- escalation study of CD-NP in heart failure patients," said Peter Strumph, Chief Executive Officer of Nile. "CD-NP has the potential to fill a large unmet medical need in the treatment of heart failure. This trial provides us our first opportunity to assess the drug's activity in heart failure patients, and to further build on our understanding of the molecule's mechanism of action."

The primary objectives of the study are to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. Safety assessments include measurement of blood pressure, heart rate, serum potassium and kidney function as calculated by glomerular filtration rate (GFR). Clinical assessments include urine flow rate, sodium excretion rate and plasma cGMP, a secondary messenger of the target receptor. The trial is expected to enroll up to approximately 35 patients. Results from the trial are expected to be available in 2008.

About CD-NP

CD-NP is a rationally-designed synthetic peptide that combines selected components of naturally occurring natriuretic peptides to create a novel, NPR- B agonist which has a favorable pharmacological profile with potent renal enhancement and cardiac unloading properties, but minimal hypotensive effects. Data from Nile's recently completed Phase Ia study in 22 healthy volunteers was consistent with several pre-clinical findings, including that CD-NP was associated with increased levels of plasma cGMP, a secondary messenger of the target
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
2. Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation
3. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
5. Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
6. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
7. Transition Therapeutics Announces Appointment of Vice-President of Business Development
8. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
9. Transition Therapeutics Announces Milestone Payment from Elan
10. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
11. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... York, NY (PRWEB) July 26, 2014 ... Infosecurity magazine on July 23rd, new research by Palo ... starting to rewrite their playbook, now focusing more on ... en masse who have become increasingly wise to their ... founder and CEO/CTO, Joe Caruso, talks about the ...
(Date:7/26/2014)... ON (PRWEB) July 26, 2014 Studio B ... type of implant, often called Teeth in a Day, gives ... with a full set of bright, pearly whites with very ... teeth are permanent, look and feel just like natural teeth, ... and regular checkups. Studio B Dental is one of ...
(Date:7/26/2014)... 2014 According to the Banish My ... a comprehensive guide that covers detailed instructions on how ... the need of any medication. , Vkool reveals ... and safe remedies for relieving symptoms of keratosis pilaris ...     How to treat children's keratosis pilaris ...
(Date:7/25/2014)... 26, 2014 PersonalInjurySolicitorsIreland, a legal ... to people who have suffered from a variety ... both their new company, and a website, ... new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the law ... of the company is always on the client, ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6Health News:Studio B Dental Improves Patient Smiles with All-on-Four Dental Implants 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2
... in diagnosing the condition, study says , , FRIDAY, Sept. 28 ... before, during or after pregnancy, a new study finds. , ... her baby and her entire family, according to the report ... of Psychiatry . , "The prevalence of women diagnosed with ...
... with important information on the use, of aspirin in the prevention ... ... strokes -, SILVER SPRING, Md., Sept. 28 Discovery Health ... and,secondary prevention of cardiovascular and cerebral-vascular events.,Premiering Sunday, September 30, at 9 ...
... Simcere,s Leading Position in China,s Stroke ... ... -- Simcere Pharmaceutical,Group (NYSE: SCR; "Simcere"), the manufacturer of the ... generic pharmaceuticals in China, today announced that it has,entered into ...
... for Medical Equipment/Healthcare IT, Facility Design Consulting, Building ... and NEW YORK, Sept. 28 ,Susquehanna Health has ... range,of technology and service solutions for a master ... Valley Hospital, Divine,Providence Hospital, Hepburn Plaza and The ...
... GOLDEN, Colo., Sept. 28 ABR-Affinity,BioReagents, a ... an expanded 100% Quality Guarantee. Launched ... was,established to bolster confidence in research antibodies. ... building blocks of early-stage life science,research and ...
... With audience members cheering and,famous Chicago chefs watching their ... the finalists at Consorta,s Battle of the Hospital,Chefs. ... organic cucumbers he,serves the patients at Saint Mary,s Health ... Gold Chef Award, becoming the reigning champion of,chefs among ...
Cached Medicine News:Health News:15% of Women Struggle With Pregnancy-Related Depression 2Health News:15% of Women Struggle With Pregnancy-Related Depression 3Health News:Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits 2Health News:Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits 3Health News:Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits 4Health News:Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd. 2Health News:Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd. 3Health News:Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd. 4Health News:Susquehanna Health and Siemens Announce Plans to Improve Hospital Facilities Through Technology Investment 2Health News:Susquehanna Health and Siemens Announce Plans to Improve Hospital Facilities Through Technology Investment 3Health News:ABR-Affinity BioReagents Expands 100% Quality Guarantee 2Health News:National Battle of the Hospital Chefs Cooks Up a Winner 2
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)...  IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, July 31, 2014 to discuss ... Interested parties may access the live conference ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: